#

Back to Fluidic News & Blogs

What Are Amyloid Fibrils? Pros and Cons of Methods to Characterise Them

Thomas Kavanagh

}

September 4, 2025

 

Amyloid fibrils are among the most intriguing, and challenging, protein structures in biology. They can drive diseases like Alzheimer’s, yet also serve useful roles in nature, from bacterial biofilms to spider silk. Despite their uniform appearance, they vary widely in structure, stability, and function. This makes accurate characterisation essential, whether the goal is to stop harmful aggregation or engineer fibrils for new materials.

In this post, we’ll cover what amyloid fibrils are, why studying them matters, and how different methods compare in revealing their complex behaviour.

 

1. What Are Amyloid Fibrils?

Amyloid fibrils are highly ordered protein assemblies that form when normally soluble proteins misfold and self-assemble into elongated, thread-like structures[1]. These fibrils are characterised by a cross-β sheet architecture, where β-strands align perpendicularly to the fibril axis and stack via backbone hydrogen bonds[2]. This alignment gives amyloid fibrils their exceptional stability and distinctive morphology.

Typically, amyloid fibrils measure 5–15 nm in diameter and can extend to several microns in length[3]. Under electron or atomic force microscopy, they appear as unbranched, twisted or rope-like fibres (figure 1). Despite their structural similarities, amyloid fibrils formed by different proteins, or even by the same protein under different conditions, can vary considerably in internal structure and biological effects. This phenomenon, known as fibril polymorphism, is a key feature of amyloid biology[4,5].

Pathological vs Functional Amyloids

Not all amyloid fibrils are harmful. They can be broadly divided into two categories:

I. Pathological Amyloids

These fibrils are associated with disease, often forming in an uncontrolled and toxic manner[6]. Examples include:

    • Amyloid-β and tau in Alzheimer’s disease
    • α-synuclein in Parkinson’s disease
    • TDP-43 in ALS
    • hIAPP in type II diabetes

In many cases, it is the soluble oligomers or early intermediates, rather than the mature fibrils, that are most toxic to cells[7].

II. Functional Amyloids

Some organisms have evolved to use the amyloid fold for beneficial purposes[8]. Examples include:

    • Curli fibres in bacterial biofilms
    • Pmel17 for melanin deposition in mammals
    • Spidroins in spider silk
    • Hormone storage in secretory granules

These amyloids are highly regulated, reversible, and serve clear physiological roles[8].

Why Structure Matters

Amyloid fibrils are more than just protein tangles; they represent a profound conformational shift from disorder to order. The resulting structure is not only extremely stable and resistant to proteolysis, but also capable of templating its own formation[2,5]: a property central to disease propagation and strain diversity.

Environmental factors such as pH, ionic strength, and temperature can strongly influence fibril morphology, aggregation kinetics, and stability[9,10]. These structural features: rigidity, insolubility, and self-perpetuation, make amyloid fibrils both biologically impactful and experimentally challenging. Understanding this structural basis is the first step toward effective characterisation, whether your goal is to block fibril formation in disease or harness it for bioengineering[6-8].

 

Figure 1. Structure and Appearance of Amyloid Fibrils (A) Cross-β-sheet architecture formed by stacked β-strands perpendicular to the fibril axis. (B) Schematic representation of a twisted amyloid fibril. (C) TEM-like image showing unbranched, elongated fibrils typical of mature amyloid assemblies. These features reflect the highly ordered, stable nature of amyloid fibrils observed across diverse proteins[1-5].

2. Why Characterise Amyloid Fibrils?

Characterising amyloid fibrils is fundamental to understanding how they form, how they function: it’s essential for understanding disease mechanisms[6,7], developing new therapeutics, and harnessing fibril properties for engineered materials[8]. Despite their uniform appearance under the microscope, amyloid fibrils can differ dramatically in structure, stability, kinetics, and biological impact, depending on the protein sequence, environmental conditions, and assembly pathway[4-6]. Without careful characterisation, these differences can go unnoticed, leading to irreproducible results or misinterpretation[9].

A. Understanding Disease Mechanisms

In many neurodegenerative and systemic diseases, fibril formation is not just a consequence it’s central to the pathology[6,7]. Characterisation helps answer key questions:

    • Are the toxic species mature fibrils or intermediate oligomers? Evidence suggests that in many protein aggregation diseases, small soluble oligomers can be more harmful than mature fibrils[6,10].
    • Does a particular fibril strain propagate faster or seed more efficiently? Different fibril polymorphs can vary in seeding efficiency and propagation rates [4,5].
    • How do environmental conditions (e.g., pH, ionic strength) affect aggregation pathways? Factors such as pH, ionic strength, and temperature can influence fibril morphology, stability, and aggregation kinetics[11,12].

Detailed analysis helps link molecular structure to biological impact and is critical for identifying which species to target in therapeutic development.

B. Developing and Validating Therapeutics

Fibril-targeting strategies aim to prevent or reverse aggregation, but success depends on knowing what stage you’re affecting[6,7]:

    • Does your compound block nucleation, slow elongation, or destabilise mature fibrils?
    • Is it interacting with monomers, oligomers, or higher-order structures?

Techniques that can resolve different species and track aggregation in real time are essential for accurately mapping mechanism of action[14,15].

C. Ensuring Batch-to-Batch Reproducibility

Amyloid formation is highly sensitive to small variations in protein prep, buffer composition, and handling conditions[13,14]. Characterisation plays a crucial role in:

    • Validating that your starting material is monomeric
    • Detecting unintended fibril formation during storage or experiments
    • Ensuring consistent fibril prep across batches for downstream assays or structural studies

Without this step, results can vary from lab to lab, or even from day to day.

D. Enabling Rational Design of Functional Materials

Beyond pathology, in synthetic biology and biomaterials research, amyloid fibrils are engineered for useful properties—mechanical strength, nanostructure, or controlled self-assembly. But these properties depend critically on fibril length, stiffness, bundling, and structural regularity[8,13].

    • Are the fibrils forming as intended?
    • Are they homogeneous or mixed with off-pathway species?
    • How do small sequence changes affect assembly behaviour?

Only through rigorous characterisation can functional amyloids be designed and deployed with confidence.

3. How Do We Characterise Amyloid Fibrils?

Amyloid fibril characterisation is inherently multidimensional. No single method can capture all aspects of fibril formation—from early nucleation and intermediate species to final morphology and stability. The most robust workflows rely on complementary techniques that together build a fuller picture of the aggregation process.

Below is an overview of widely used methods, including their primary outputs, strengths, and common limitations (figure 2).

 

A. Overview of Core Techniques 

Figure 2. Overview of Common Techniques for Amyloid Fibril Characterisation. A comparison of key biophysical and structural techniques used to study amyloid fibrils. Each method provides distinct insights, ranging from secondary structure and size distribution to morphology and binding interactions. Strengths and limitations are context-dependent, highlighting the value of a complementary, multi-technique approach. MDS (Microfluidic Diffusional Sizing) offers solution-phase size measurements across the aggregation process, making it a useful addition to conventional methods [14-21].

B. Microfluidic Diffusion Sizing: Where It Fits In

Microfluidic Diffusion Sizing (MDS), as implemented in the Fluidity One-M system, measures the hydrodynamic radius of fluorescently labelled amyloid species in solution by tracking their diffusion through a laminar flow channel[20]. It is particularly effective for detecting and quantifying soluble oligomers and small fibrils in the ~1–20 nm Rh range.

Key benefits of MDS:

    • Quantitative size resolution for small, soluble amyloid assemblies
    • Detects subtle changes in size distribution during aggregation or binding
    • Requires minimal sample (4 µL) and works in native buffers
    • Enables simultaneous size and equilibrium binding (KD) measurements for amyloid–ligand interactions
    • Complements both structural techniques (TEM, AFM) and kinetic assays (ThT, CD) by bridging the gap between structural confirmation and solution-phase size quantification

C. General Recommendation: Combining Techniques for a Complete Picture

An effective amyloid characterisation workflow uses orthogonal techniques to capture structure, size, and binding information from multiple angles:

    • Use ThT or CD to follow β-sheet formation, then confirm fibril morphology with TEM or AFM.
    • Apply MDS to resolve and quantify soluble oligomers or small fibrils, particularly when working with polydisperse samples where DLS lacks resolution.
    • For binding studies, use SPR or BLI for kinetic profiling, or MDS for equilibrium affinity combined with size change detection[20].

By deliberately combining spectroscopy, imaging, and sizing methods, you can correlate aggregation onset, size evolution, and structural changes—yielding a complete, reproducible picture of amyloid behaviour[16-18,20].

Summary

Amyloid fibrils are structurally intricate, biologically significant, and experimentally challenging. Their characterisation is essential for understanding disease mechanisms, developing inhibitors, and harnessing their properties for functional materials. No single method can answer every question, but by combining orthogonal approaches, linking secondary structure, morphology, size distribution, and binding data, researchers can build a complete and reproducible picture.

Microfluidic Diffusion Sizing (MDS) adds valuable resolution to this toolbox, particularly for soluble oligomers and small fibrils that are difficult to distinguish with other solution-phase methods. When integrated alongside established spectroscopic, imaging, and interaction assays, it helps bridge the gap between structural confirmation and quantitative size analysis, enabling deeper insight into amyloid biology and its applications.

 

Learn more about MDS

 

References

  1. Chiti F, Dobson CM. Protein misfolding, functional amyloid, and human disease. Annu Rev Biochem. 2006;75:333-366. doi:10.1146/annurev.biochem.75.101304.123901
  2. Sawaya MR, Sambashivan S, et al. Atomic structures of amyloid cross-β spines reveal varied steric zippers. Nature. 2007;447(7143):453-457. doi:10.1038/nature05695
  3. Sunde M, Blake CC. The structure of amyloid fibrils by electron microscopy and X-ray diffraction. Adv Protein Chem. 1997;50:123-159. doi:10.1016/S0065-3233(08)60320-4
  4. Tycko R. Amyloid polymorphism: structural basis and neurobiological relevance. Neuron. 2015;86(3):632-645. doi:10.1016/j.neuron.2015.03.017
  5. Fitzpatrick AWP, Falcon B, et al. Cryo-EM structures of tau filaments from Alzheimer’s disease. Nature. 2017;547(7662):185-190. doi:10.1038/nature23002
  6. Benilova I, Karran E, De Strooper B. The toxic Aβ oligomer and Alzheimer’s disease: an emperor in need of clothes. Nat Neurosci. 2012;15(3):349-357. doi:10.1038/nn.3028
  7. Collinge J, Clarke AR. A general model of prion strains and their pathogenicity. Science. 2007;318(5852):930-936. doi:10.1126/science.1138718
  8. Fowler DM, Koulov AV, Balch WE, et al. Functional amyloid — from bacteria to humans. Trends Biochem Sci. 2007;32(5):217-224. doi:10.1016/j.tibs.2007.03.003
  9. Knowles TPJ, Vendruscolo M, Dobson CM. The amyloid state and its association with protein misfolding diseases. Nat Rev Mol Cell Biol. 2014;15(6):384-396. doi:10.1038/nrm3810
  10. Bolognesi B, Kumita JR, Barros TP, et al. ANS binding reveals common features of cytotoxic amyloid species. ACS Chem Biol . 2010 Aug 20;5(8):735-40. doi: 10.1021/cb1001203.
  11. Uversky VN, Li J, Fink AL. Conformational constraints for amyloid fibrillation: the importance of being unfolded. Biochim Biophys Acta. 2004 May 6;1698(2):131-53. doi: 10.1016/j.bbapap.2003.12.008.
  12. Fändrich M, Schmidt M, Grigorieff N. Recent progress in understanding Alzheimer’s β-amyloid structures. Trends Biochem Sci. 2011;36(6):338-345. doi:10.1016/j.tibs.2011.02.002
  13. Morris AM, Watzky MA, Finke RG. Protein aggregation kinetics, mechanism, and curve-fitting: a review of the literature. Biochim Biophys Acta. 2009;1794(3):375-397. doi:10.1016/j.bbapap.2008.10.016
  14. Nielsen L, Khurana R, Coats A, et al. Effect of environmental factors on the kinetics of insulin fibril formation: elucidation of the molecular mechanism. Biochemistry. 2001;40(20):6036-6046. doi:10.1021/bi002555c
  15. LeVine H 3rd. Thioflavine T interaction with synthetic Alzheimer’s disease β-amyloid peptides: detection of amyloid aggregation in solution. Protein Sci. 1993;2(3):404-410. doi:10.1002/pro.5560020312
  16. Wallace MI, Ying L, Balasubramanian S, Klenerman D. FRET fluctuation spectroscopy: exploring the conformational dynamics of a DNA hairpin loop. J Phys Chem B 104(48):11551-11555DOI:10.1021/jp001560n
  17. Rich RL, Myszka DG. Survey of the year 2007 commercial optical biosensor literature. J Mol Recognit. 2008 Nov-Dec;21(6):355-400.doi: 10.1002/jmr.928.
  18. Sultana A, Lee JE. Measuring protein–protein and protein–nucleic acid interactions by biolayer interferometry. Curr Protoc Protein Sci. 2015;79:19.25.1–19.25.26. doi:10.1002/0471140864.ps1925s79
  19. Xue WF, Homans SW, Radford SE. Systematic analysis of nucleation-dependent polymerization: a case study on amyloid fibril formation. Proc Natl Acad Sci U S A. 2008 Jul 1;105(26):8926-31. doi: 10.1073/pnas.0711664105.
  20. Arosio P, Müller T, Rajah L, et al. Microfluidic diffusion analysis of the sizes and interactions of proteins under native solution conditions. ACS Nano. 2016;10(1):333-341. doi:10.1021/acsnano.5b04713
Fluidic Sciences Ltd